On March 3, 2026, the United States Court of Appeals for the Federal Circuit issued a nonprecedential opinion in Medivis, Inc. v. Novarad Corp., No. 2024-1794, affirming the Patent Trial and Appeal Board’s (“Board”) finding of no anticipation but reversing and remanding on the issue of obviousness.